A carregar...
Combination of an allosteric Akt inhibitor MK-2206 with etoposide or rapamycin enhances the anti-tumor growth effect in Neuroblastoma.
BACKGROUND: Activation of Akt is a marker of decreased event-free or overall survival in neuroblastoma (NB) patients. MK-2206, a novel allosteric Akt inhibitor, is now tested in clinical trials in adult cancers. In this study, effect of MK-2206 on tumor growth and murine survival, alone or in combin...
Na minha lista:
| Publicado no: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693338/ https://ncbi.nlm.nih.gov/pubmed/22550167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3321 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|